Insomnia …

Laura Palagini MD PhD

Sleep Disorders

Updated 05.26.2024
Released 11.01.2000
Expires For CME 05.26.2027

Insomnia

Author: Laura Palagini MD PhD

See Contributor Disclosures

Editor: Federica Provini MD

Insomnia

In This Article

Quick Link

Introduction

Overview

Insomnia symptoms are the most frequent sleep disturbances and may affect more than 30% of the population; insomnia potentially affects nearly everyone occasionally. Ten percent become chronic, with negative consequences on mental and physical health. New models, new classifications, and new treatment options have emerged during the last few years and may change these negative trajectories correlated to insomnia.

Key points

	• Diagnostic classification systems of insomnia have changed and finally define insomnia as a separate and independent condition known as “insomnia disorder” and not as a secondary condition.
	• Symptoms of insomnia are not limited to the night; insomnia is now considered a “24-hour disorder” with nighttime and daytime symptoms.
	• Hyperarousal, such as the hyperactivation of the stress system at a central and peripheral level, is the mechanism sustaining the cycle of chronic insomnia.
	• Cognitive behavioral therapy for insomnia is the first-line treatment, but it is not so widespread. In some countries, pharmacological treatment is still the first option.
	• Advances in pharmacological options have been made during the last 10 years, and the pharmacological armamentarium for insomnia is now wider.

Historical note and terminology

Insomnia, the difficulty in initiating or maintaining sleep, was first recorded in Egyptian medical papyri, with use of opium as a hypnotic to relieve insomnia and lavender as herbal sleep remedy in addition to its use for preserving mummies in the belief that death is eternal sleep (03). The ancient Indian text on Ayurvedic medicine, Charaka Samhita, written around 600 BC, describes herbal remedies for insomnia as well as nonpharmacological measures such as massage, warm bath, drinking milk, and listening to music. Although sleep disorders were known in ancient Chinese medicine, systematic description of these including insomnia was recorded in Huangdi Neijing (407-310 BC), with use of herbs and acupuncture for treatment. In Greek medicine, insomnia is reflected in Aristotle’s writings on sleeplessness in 350 BC (11). In Arab medicine, Avicenna’s Canon of Medicine, which was written in 1632 AD, described behavioral as well as pharmacological approaches for the treatment of insomnia.

More recently and until 2013, insomnia was considered and classified as a secondary condition to mental disorder or considered a primary form based on psychological factors. From 2013, major classification systems have classified insomnia as an independent disorder, emphasizing the concept of comorbidity compared to causality (primary or secondary). This new important classification was built thanks to the development of important models of insomnia. In the last 30 years, the notion has emerged that insomnia is a stress-related disorder with neurobiological, genetic, and psychological predisposing factors, and the 3Ps model, ie, predisposing, precipitating and perpetuating, has been developed (29). The neurobiological mechanism has been clarified and correlated to hyperarousal, and insomnia is emerging as a complex neurobiological disorder (25; 21; 31).

The International Classification of Sleep Disorders, 3rd edition (ICSD-3), was published by the American Academy of Sleep Medicine and is increasingly used by sleep physicians in the United States (01). The classification of insomnia disorders in ICSD-3 is a marked departure from that of prior systems. In ICSD-1 and ICSD-2, primary insomnia was further subtyped into psychophysiologic, idiopathic, and paradoxical (sleep-state misperception) insomnia disorders. The diagnostic reliability and validity of insomnia diagnoses, especially primary insomnia, have been challenged on the basis of several studies, and the ICSD-3 has included all insomnia diagnoses, ie, primary and comorbid, under a single, chronic insomnia disorder (26). The three categories now are:

(1) Chronic insomnia disorder
(2) Short-term insomnia disorder
(3) Other insomnia disorder

The Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5 and DSM-5 text revision), has been produced by the American Psychiatric Association and is more likely to be used by biological and psychiatric specialists (02). The DSM emphasizes the need for independent clinical attention of a sleep disorder regardless of mental or other medical problems that may be present. Two previous diagnoses—sleep disorder related to another mental disorder and sleep disorder related to another medical condition—have been eliminated, and greater specificity of coexisting conditions is provided for each of the 10 sleep-wake disorders defined, including insomnia. Starting from DSM-5, primary insomnia has been replaced with a diagnosis of insomnia disorder, a switch to avoid the primary/secondary designation when this disorder co-occurs with other conditions and to reflect changes throughout the classification.

Clinical manifestations

Prognosis and complications

Insomnia is often a chronic condition, with retrospective reports indicating that about 80% of severely affected individuals have had the problem for longer than 1 year, and approximately 40% report a duration of longer than 5 years. Longitudinal studies suggest that 30% to 80% of those identified with moderate to severe insomnia show no significant remission over time.

Prolonged insomnia is associated with an increased risk of unipolar major depression, bipolar depression, anxiety, and substance use disorder and may be an independent risk factor for heart disease, hypertension, and diabetes, particularly when sleep time is less than 6 hours per night (07; 09).

Complications of insomnia include impaired responses to infections, increase in inflammation, higher levels of the stress hormone cortisol, and other biomarkers related to fatigue and poor health. Pain is recognized as a cause of sleep disturbances.

Clinical vignette

A 43-year-old woman presented to her primary care physician for a routine appointment. A screening history revealed complaints of poor nighttime sleep resulting in excessive fatigue, increased irritability, and difficulty concentrating.

A sleep questionnaire and detailed history revealed 8 years of difficulty initiating and maintaining sleep, progressively worsening. The onset of her sleep problems coincided with the birth of her first child. The patient had needed to rise several times during the night to feed her baby; however, her sleep problems did not remit when the child began sleeping through the night. The patient had attempted to treat her insomnia with sleep medication but was unable to find a drug that had tolerable side effects; many of the medications she tried left her feeling groggy and “hungover” the following day.

It typically took the patient about 60 to 90 minutes to fall asleep. She reported waking up spontaneously two to three times per night and, subsequently, had difficulty falling asleep; she reported spending up to 3 hours awake during the night. She had difficulty functioning at work as a schoolteacher due to increased fatigue and poor concentration.

The patient reported a history of hypothyroidism but stated that this was adequately controlled with medication. She denied any other medical conditions that could potentially interfere with sleep. Her husband described occasional soft snoring but denied any other notable nighttime behaviors.

Her sleep logs revealed a pattern consistent with an insomnia disorder, with extended time to fall asleep and extended awakenings throughout the night. She would attempt to nap two to three times per week but would be unable to fall asleep after lying down. Her sleep schedule was regular, but she tended to go to bed earlier on nights following a particularly bad night of sleep and attempted to sleep in on the weekends.

Her self-report and her husband’s report of nighttime symptoms were not consistent with obstructive sleep apnea or any other occult sleep disorder; therefore, referral for an overnight sleep study was unwarranted.

The patient was followed for five biweekly sessions of cognitive behavioral therapy for insomnia. This treatment consisted of stimulus control therapy, sleep restriction therapy, sleep hygiene education, and cognitive therapy in addition to a final session reviewing techniques to maintain treatment gains and prevent relapse. Within the first 2 weeks of treatment, the patient began sleeping more solidly and noticed improvements in daytime fatigue and alertness. Her sleep continued to improve as sleep opportunity was gradually expanded. Treatment was discontinued when the patient reported that she was getting an adequate amount of sleep and was no longer experiencing daytime symptoms. At a later follow-up appointment, the patient reported that despite occasional nights of poor sleep related to transient stressors, she could maintain the gains she made in treatment. She reported that she was falling asleep more quickly and no longer waking up during the night.

Biological basis

	• Interaction of predisposing and precipitating factors may favor acute insomnia; perpetuating factors maintain chronic insomnia in a self-reinforcing loop.
	• Hyperarousal, the hyperactivation of stress and the inflammatory system, is the mechanism perpetuating the cycle of insomnia.
	• Deficient GABAergic system, declining melatonin production, and overactivation of the orexin system have been hypothesized in insomnia.
	• Chronic insomnia may favor a state of allostatic overload, impairing neural plasticity and immune and endocrine pathways, and may contribute to mental and physical disorders.

Current evidence for the pathophysiology of insomnia converges on the hypothesis that it is a stress-related disorder according to the diathesis-stress model, with hyperarousal as a key factor (25; 21; 22). In fact, evidence for increased CNS brain metabolism, sympathetic activity, high-frequency EEG activation and REM density, and activation of arousal-promoting neurotransmission consistent with the central and peripheral hyperactivation of stress and inflammatory systems, have been shown in insomnia (25; 21; 22). Therefore, insomnia is considered a stressor that impairs neuroplasticity, leading to a state of allostatic overload, favoring medical and psychiatric disorders (12).

In this framework, the hyperactivity of the HPA axis has consistently been demonstrated to be related to a functional reduction of the cortical GABAergic system and with deficient GABAergic synapses associated with CNS hyperarousal in insomnia. Increased GABA levels in subjects suffering from insomnia have been found and may reflect a potential compensatory allostatic response to chronic hyperarousal.

Maladaptive changes in neuroplasticity are hypothesized in insomnia, reflecting GABAergic alterations (15). In particular, insomnia is associated with a reduction in slow-wave sleep and diminished sleep-related consolidation of declarative and procedural memories. As impaired neuroplasticity favors the accumulation of neurotoxic proteins, neuroinflammation, and stress system alterations, insomnia is considered to be a causal factor in neurodegenerative (28) and neuropsychiatric disorders (19).

In addition, few data in animals and humans have reported that disrupted sleep and insomnia may be related to the overactivation of the orexinergic system. Some more consistent data in humans and animals reported the overactivation of orexins in response to acute stress and in stress-related disorders. Taken together, these findings may lead to the hypothesis that an orexin overactivation may be associated with stress-related hyperarousal and the hyperactivation of arousal-promoting systems in insomnia (18).

Other hypotheses are related to melatonin production. The production of melatonin generally decreases with age, and it is related to an increase in insomnia prevalence in the elderly. This relationship between increasing age, declining melatonin production, and increasing insomnia prevalence has led to the “melatonin-replacement” hypothesis. In this framework, treatments with melatonin may replenish the deficiency in the endogenous hormone involved in sleep promotion and may improve overall sleep quality (34). In summary, current models of insomnia hypothesize that wake-promoting transmitters like orexin, catecholamine, and histamine may be hyperactivated, whereas sleep-promoting neurotransmitters like GABA, adenosine, and melatonin may be deficient.

A downward spiral of insufficient overnight adaptation to distress resulting in accumulating hyperarousal, which, in turn, impedes restful REM sleep has been hypothesized in insomnia. REM sleep dysregulation and its negative consequences on emotion and cognition have been related to a dysfunctional stress response in insomnia (31; 24).

Persistent hyperactivity in the ventral emotional system that includes the amygdala has been described in insomnia-related hyperarousal with dysfunctional top-down regulation of emotions (25; 21; 22).

Etiology and pathogenesis

Current models recognize insomnia in the framework of the diathesis-stress model with predisposing, precipitating, and perpetuating factors for insomnia (Table 1). Predisposing factors interact with precipitating factors for developing acute insomnia. Perpetuating factors contribute to insomnia chronicity. A downward spiral of insufficient overnight adaptation to distress maintains the cycle of insomnia.

Table 1. Insomnia Disorder

	A. Predisposing factors
		• Aging: sleep fragmentation and reduction in melatonin production • Young age: circadian rhythm delay • Female sex: menstrual cycle, pregnancy, and menopause • Behavioral: hyperarousal and tendency to worry • Genetic factors: genetic variations affecting sleep • Other sleep disorders, such as sleep apnea and circadian rhythm disorders • Medical and neuropsychiatric disorders
	B. Precipitating factors
		• Medical or psychiatric illness • Daily life stressors or major stressors (for example COVID-19)
	C. Perpetuating factors
		• Hyperarousal cognitive and somatic • Poor coping with short-term insomnia leading to development of chronic insomnia • Excessive napping during the day • Unnecessary preoccupation and worry about sleep that perpetuates insomnia

Behavioral model of insomnia

Predisposing factors for developing insomnia may include traits such as chronic hyperarousal and proneness to worry or rumination. Precipitating factors are events or acute stressors that interact with predisposing factors to caus...

Neurologic/psychiatric disorders with comorbid insomnia. The following are some examples of such disorders:

Alzheimer disease. Sleep disorders occur in 20% to 50% of patients, and the most common problem is difficulty in falling and staying asleep. There is increased duration and frequency of awakening during night.

Parkinson disease. Sleep disorders occur in 1% to 5% of patients, and incidence increases with age. Insomnia is due to tremors, painful dystonia, nocturia, depression, and medications.

Epilepsy. Approximately 25% of patients with epilepsy have seizures during sleep. Epileptic seizures may cause recurrent dreams, nightmares, and frequent arousals that may result in awakenings and a complaint of insomnia.

Ischemic stroke. Insomnia or excessive sleepiness and sleep disordered breathing are frequently seen in patients who have an ischemic stroke.

Mood disorders. Insomnia is a comorbid condition in mood disorders and a clinically significant feature that is highly prevalent across patients’ entire course. As many as 80% to 100% of people during the depressive episode period, and 45% to 55% during the bipolar inter-episode period, experience insomnia. Insomnia can be related to illness severity, cognitive dysfunctions, levels of hopelessness, low levels of resilience, increased risk of substance abuse, aggressive and impulsive behaviors, emotional dysregulation, and increased suicidal risk. In addition, it plays an important role in relapses and recurrences; it is considered an independent risk factor as well as an early sign occurring prior to both depressive and manic episodes. Insomnia as a comorbidity in patients with psychiatric disorders is associated with a more adverse course and lower response rates to treatment (19).

Anxiety disorders. Insomnia is a major predictor for the onset of anxiety (07). Insomnia is highly prevalent in individuals experiencing anxiety and affects more than 80% of patients with general anxiety disorder and 70% with panic disorder. It is an indicator of increased morbidity and low responsiveness to treatment, and it is related to the severity of worry, fear, and hypervigilance (19).

Genetics and epigenetics of insomnia. A genetic and epigenetic model of insomnia has been revised (17). Insomnia is emerging as a complex stress-related sleep disorder with polygenic etiology (32). Twin and family studies have shown that insomnia may run in a family. It is moderately heritable, with a heritability of 40%, and is stable across time. Heritability is stronger in females than in males.

Studies have suggested that genes may play a role in the development of insomnia symptoms, especially for women, but also underline the potential role of environmental influences in insomnia. In this framework, the sleep reactivity, such as the extent of insomnia development after a stressor, has emerged as an important heritable trait in insomnia influencing the degree of “arousability” after a stressor. Data on candidate genes and genome-wide association studies may confirm that insomnia has a polygenic etiology, and it is currently listed as one of the most polygenic traits, following major depressive disorder (32). Several variants have been observed in genes regulating neural function, brain regions, immune responses, nervous system development, processes of neurodegeneration, and epigenetic modifications in insomnia. Importantly, variants have been observed in circadian regulating genes, such as CLOCK 3111 T/C, PER1, PER2, and PER3; in genes involved in serotonin regulation; in genes regulating orexin receptors; and in genes regulating BDNF. Indeed, it is estimated that current genome-wide association study SNPs explain 17.3% of the total heritability, suggesting a strong role of genes and environmental interactions in insomnia. The importance of the role of the interaction between stressors and genes involved in insomnia is emerging, such as circadian genes or genes involved in serotonin functioning. In this framework, an epigenetic model of insomnia would be useful. It may explain the complexity of this stress-related disorder’s “arousability” after a stressor. Epigenetic data on insomnia are lacking, but results of a distinct pattern of DNA methylation in disturbed sleep after psychosocial stressors has been shown in humans. Also, data on distinct patterns of DNA methylation in fragmented sleep and insufficient sleep may be helpful for understanding insomnia. Additionally, epigenetic data on the effect of acute sleep loss and on sleep deprivation may suggest that when insomnia is established, it may favor a change in DNA expression, as well as possibly contribute to insomnia chronicity.

Importantly, insomnia symptoms may share some genetic influence with factors contributing to some psychiatric disorders. They may be a part of the same genetic cluster correlated with insomnia. Like other mental and stress-related disorders, the polygenic risk of insomnia may be a causal factor in some psychiatric and medical disorders, as well as long-term consequences on the brain of genes and environmental interactions in insomnia.

Management

	• History and correct diagnosis are important for planning treatment of insomnia.
	• Cognitive behavioral therapy is the first-line option.
	• Several drugs with different mechanisms of action are available for treatment of insomnia.
	• Various approaches can be combined.

According to previous international guidelines, primary treatment goals in subjects with insomnia should be to improve sleep quality and quantity and to improve insomnia-related daytime impairments (27; 18; 23). Other sleep-specific outcomes should include the improvement of wake time after sleep onset (WASO), sleep onset latency (SOL), number of awakenings, total sleep time (TST), or sleep efficiency.

A correct diagnosis fostered by thorough and competent evaluation is one of the most important considerations regarding treatment. Secondary causes that need specific treatment (apnea, restless legs syndrome, etc.) must be identified and addressed directly.

Cognitive behavioral therapy for insomnia. Cognitive behavioral therapy for insomnia (CBT-I) has received support from several studies as an effective treatment for insomnia, and it is currently the first-line treatment. CBT-I is a multicomponent intervention that addresses behavioral and psychological factors that contribute to the development and maintenance of insomnia. Two core components of CBT-I are stimulus control therapy and sleep restriction therapy. Stimulus control therapy is a behavioral strategy that aims to “reconnect” the sleeping quarters with the act of sleeping. Patients are advised to use the bed only for sleeping or for sexual relations. If unable to sleep, the patient should get out of the bed and engage in a low-level, low-light activity (04). Sleep restriction therapy makes therapeutic use of the increased sleep pressure associated with a restricted opportunity for sleep, typically approximately 6 hours per 24-hour period. Patients should be advised that this technique is designed to enhance sleepiness and are warned to use appropriate caution to avoid accidents when undertaking this treatment plan. Education about sleep hygiene is often included as a component of CBT-I. Examples of sleep hygiene instructions include limiting the variability of bedtime and risetime with a regular sleep-wake schedule, avoiding daytime naps, and avoiding caffeine and bright light exposure toward the end of the day. The cognitive component of CBT-I serves to identify and modify any maladaptive beliefs or thoughts the patient has about sleep, including setting realistic expectations regarding sleep patterns and next-day consequences of sleep loss. CBT-I may also include adjunctive treatments such as relaxation training or light therapy as needed.

A meta-analysis suggests that it is an effective treatment for insomnia sufferers with comorbid psychiatric conditions (08). CBT-I has also been shown to be effective in treating patients with insomnia that is comorbid with medical illness (06). Research suggests that CBT-I may be useful in treating insomnia associated with breast cancer (30), chronic pain (10), and fibromyalgia (14). Indeed, CBT-I is not widespread across countries, and it is not often available. Pharmacotherapy remains the first option in the majority of countries.

Pharmacotherapy. The pharmacological principles related to the treatment of insomnia are highly complex, and voluminous literature exists on this topic. The choice of pharmacologic agents should be directed by symptom pattern, treatment goals, past treatment responses, patient preference, cost, availability of other treatments, comorbid conditions, contraindications, and side effects. Drugs approved for insomnia treatment according to international guidelines are gamma-aminobutyric acid (GABAa) receptor agonists, melatonin receptor agonists, and orexin receptor antagonists. Other compounds, such as antidepressants, antihistamines, antipsychotics, or antiepileptics, should not be considered first-line treatment options for insomnia. Indeed, low doses (subtherapeutic for depression) of sedating tricyclics, particularly amitriptyline, dosulepin, and doxepin, have been used to treat insomnia for decades. Only doxepin has received the recommendation for insomnia treatment, but it is not available in all countries. Trazodone is an antagonist at 5HT1a, 5HT2, and a1 adrenergic receptors as well as a weak 5HT reuptake inhibitor; it is the second most prescribed medication for insomnia in the U.S., but data for its use are limited.

Gamma-aminobutyric acid (GABAa) receptor agonists include short/intermediate benzodiazepines (brotizolam, lormetazepam, temazepam, triazolam) and nonbenzodiazepine compounds, the so-called Z-drugs, including zolpidem, zaleplon, zopiclone, and eszopiclone. They were found to be effective for short-term use and to be equally effective in improving SOL, WASO, TST, and sleep efficiency. In particular, an extended-release formulation of zolpidem has shown good results in improving WASO. Among Z-drugs is the emerging role of eszopiclone; treatments can last until 6 months, and lots of data recognize its use in comorbid psychiatric conditions. A variety of side effects have been reported with respect to these classes of drugs, including hangover, nocturnal confusion, falls, negative effects on next‐day cognitive performances, rebound insomnia, tolerance, and dependency. Z-drugs have been reported with the risk of severe parasomnia. Indeed, insomnia is often long lasting and is often treated with these hypnotic compounds for long periods in clinical practice. Still, the longer-term safety and efficacy of these hypnotics remain uncertain, except for eszopiclone. Trying intermittent use or using CBT-I or prolonged release melatonin 2 mg during tapering has been suggested.

Among melatonin receptors, M1 and M2 agonists prolonged-release melatonin 2 mg and ramelteon have been approved for insomnia treatment. Melatonin receptor agonist prolonged-release melatonin 2 mg has been shown to mimic the physiological release of melatonin by releasing melatonin gradually and acting on melatonin receptors. Prolonged-release melatonin 2 mg has been shown to be effective in improving SOL, WASO, TST, and sleep efficiency and to reduce night awakenings without altering the physiological sleep structure. Prolonged-release melatonin 2 mg has been shown to be well tolerated and is not associated with impairment of psychomotor functions, memory recall, and driving skills. It has not shown side effects, such as hangover, nocturnal confusion and falls, negative effects on next‐day cognitive performance, rebound insomnia, tolerance, and dependency. In some countries, prolonged-release melatonin 2 mg has been approved for the treatment of chronic insomnia in people aged 55 or older. Ramelteon has been shown to be effective on SOL, WASO, and TST. Indeed, it is not available in most countries (13).

The newest molecules for the treatment of insomnia are dual orexin receptor antagonists (DORA) OX1R and OX2R, which are G protein–coupled receptors. OX1R and OX2R mRNAs are widely expressed in the brain in a pattern similar to that of orexin nerve terminals. There are few studies showing that OX1R antagonists are involved in regulating the stress system and that anxiety-like behaviors are involved in hyperarousal. Inhibition of OX1R attenuated cage-exchange stress-induced hyperarousal and anxiety-like behaviors, whereas selective inhibition of OX2R prevented ACTH release elicited by psychological stress in mice, suggesting that both OX1R and OX2R are specific targets in preventing the overactivation of the arousal system and HPA axis, respectively, under stress (18).

It has been hypothesized that antagonizing both orexin receptors would elicit the most powerful sleep-promoting effects; therefore, many of the studies around orexin antagonists have focused on DORAs. Inhibition of both OX1R and OX2R DORAs regulates REM and NREM sleep processes and contributes to restoring alterations in sleep-related insomnia and, in turn, promoting physiological sleep. This may be vital to reactivate sleep and its functions, which could be useful for stress and emotion regulation as well. By acting on the transition between wake and sleep, it is possible that DORAs may reset the flip-flop switch mechanism in insomnia, which has been hypothesized to be impaired. All these functions may prove pivotal for regulating sleep processes, sleep-dependent brain plasticity, and stress/emotional reactivity in insomnia and, in turn, contributing to “switching off” hyperarousal in insomnia (17). Approved DORAs for insomnia treatment are suvorexant, lemborexant, and daridorexant. Their use may also improve insomnia symptoms when it is comorbid with mental and neurologic disorders (05).

Drugs used in the past for the treatment of insomnia, as well as those currently used, are listed in Table 2.

Table 2. Drugs Used for the Treatment of Insomnia

Drug	Mechanism of action
Short- and medium-acting benzodiazepines	Binding to GABA-A receptors
Prolonged-release melatonin 2 mg	Agonist at melatonin MT1 and MT2 receptors
Ramelteon	Agonists at melatonin MT1 and MT2 receptors
Daridorexant Lemborexant Suvorexant	Selective, dual orexin receptor antagonists
Zaleplon/nonbenzodiazepine hypnotic	Modulation of GABA-A receptor
Zolpidem/nonbenzodiazepine hypnotic	Modulation of GABA-A receptor
Zopliclone/eszopliclone, nonbenzodiazepine	Modulation of GABA-A receptor

Sedating medications should be used with caution in the elderly due to evidence suggesting an increased risk for falls in this population. The aforementioned are recommended for use according to the AASM clinical practice guidelines based on level of evidence for the pharmacologic treatment of chronic insomnia in adults, which is weak as compared to no treatment (27).

Combination of CBT-I with other therapies. A retrospective observational study has shown that efficacy of cognitive behavioral therapy combined with eszopiclone for the treatment of sleep disorders patients transferred out of the intensive care unit was better than use of eszopiclone alone (33).

References

01: American Academy of Sleep Medicine. International classification of sleep disorders: Diagnostic and coding manual. 3rd edition. Darien, IL: American Academy of Sleep Medicine, 2014.
02: American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. Arlington, VA: American Psychiatric Association, 2013.
03: Asaad T. Sleep in ancient Egypt. In: Chokroverty S, Billiard M, editors. Sleep Medicine. New York, Springer, 2015.
04: Bootzin R, Smith L, Franzen P, Shapiro S. Stimulus control therapy. In: Sateia MJ, Buysse DJ, editors. Insomnia: Diagnosis and Treatment. London: Informa Healthcare, 2010:268-76.
05: Carpi M, Palagini L, Fernandes M, et al. Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities. Neuropharmacology 2024;245:109815. PMID 38114045
06: Dolan D, Taylor D, Bramoweth A, Rosenthal L. Cognitive-behavioral therapy of insomnia: a clinical case series study of patients with co-morbid disorders and using hypnotic medications. Behav Res Ther 2010;48(4):321-7. PMID 20074701
07: Hertenstein E, Feige B, Gmeiner T, et al. Insomnia as a predictor of mental disorders: a systematic review and meta-analysis. Sleep Med Rev 2019;43:96-105 ** PMID 30537570
08: Hertenstein E, Trinca E, Wunderlin M, et al. Cognitive behavioral therapy for insomnia in patients with mental disorders and comorbid insomnia: a systematic review and meta-analysis. Sleep Med Rev 2022;62:101597. PMID 35240417
09: Johnson KA, Gordon CJ, Chapman JL, et al. The association of insomnia disorder characterized by objective short sleep duration with hypertension, diabetes, and body mass index: a systematic review and meta-analysis. Sleep Med Rev 2021;59:101456. PMID 33640704
10: Jungquist C, O’Brien C, Matteson-Rusby S, et al. The efficacy of cognitive-behavioral therapy for insomnia in patients with chronic pain. Sleep Med 2010;11(3):302-9. PMID 20133188
11: Kryger M, Lavie P, Rosen R. Recognition and diagnosis of insomnia. Sleep 1999;22(3):S421-6.
12: Lo Martire V, Caruso D, Palagini L, Zoccoli G, Bastianini S. Stress & sleep: a relationship lasting a lifetime. Neurosci Biobehav Rev 2020;117:65-77. PMID 31491473
13: Maruani J, Reynaud E, Chambe J, Palagini L, Bourgin P, Geoffroy PA. Efficacy of melatonin and ramelteon for the acute and long-term management of insomnia disorder in adults: A systematic review and meta-analysis. J Sleep Res 2023;32(6):e13939. PMID 37434463
14: Miró E, Lupiáñez J, Martínez M, et al. Cognitive-behavioral therapy for insomnia improves attentional function in fibromyalgia syndrome: a pilot, randomized controlled trial. J Health Psychol 2011;16(5):770-82. PMID 21346020
15: Palagini L, Bianchini C. Pharmacotherapeutic management of insomnia and effects on sleep processes, neural plasticity, and brain systems modulating stress: a narrative review. Front Neurosci 2022;16:893015. PMID 35968380
16: Palagini L, Bramante A, Baglioni C, et al. Insomnia evaluation and treatment during peripartum: a joint position paper from the European Insomnia Network task force "Sleep and Women," the Italian Marcè Society and international experts task force for perinatal mental health. Arch Womens Ment Health 2022a;25(3):561-75. PMID 35419652
17: Palagini L, Cipriani E, Caruso V, et al. Insomnia during the perinatal period and its association with maternal and infant psychopathology: a systematic review and meta-analysis. Curr Psychiatry Rep 2023a;25(11):617-41. PMID 37819491
18: Palagini L, Geoffroy PA, Balestrieri M, et al. Current models of insomnia disorder: a theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment. J Sleep Res 2023b;32(4):e13825. PMID 36786121
19: Palagini L, Hertenstein E, Riemann D, Nissen C. Sleep, insomnia and mental health. J Sleep Res 2022b;31(4):e13628. PMID 35506356
20: Palagini L, Manni R, Liguori C, et al. Evaluation and management of insomnia in the clinical practice in Italy: a 2023 update from the Insomnia Expert Consensus Group. J Neurol 2024;271(4):1668-79. PMID 38063870
21: Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res 2017;26(6):675-700. PMID 28875581
22: Riemann D, Benz F, Dressle RJ, et al. Insomnia disorder: State of the science and challenges for the future. J Sleep Res 2022;31(4):e13604. PMID 35460140
23: Riemann D, Dressle RJ, Benz F, Palagini L, Feige B. The psychoneurobiology of insomnia: hyperarousal and REM sleep instability. Clin Transl Neurosci 2023;7:30. Available at: https://www.researchgate.net/publication/374234218_The_Psychoneurobiology_of_Insomnia_Hyperarousal_and_REM_Sleep_Instability Accessed May 15, 2024.
24: Riemann D, Espie CA, Altena E, et al. The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. Sleep Res 2023;32(6):e14035. PMID 38016484
25: Riemann D, Perlis M. The treatments of chronic insomnia: a review of benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep Med Rev 2009;13(3):205-14. PMID 19201632
26: Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest 2014;146(5):1387-94. PMID 25367475
27: Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice guideline. J Clin Sleep Med 2017;13(2):307-49.** PMID 27998379
28: Shamim SA, Warriach ZI, Tariq MA, Rana KF, Malik BH. Insomnia: risk factor for neurodegenerative diseases. Cureus 2019;11(10):e6004. PMID 31807391
29: Spielman A, Caruso L, Glovinsky P. A behavioral perspective on insomnia treatment. Psychiatr Clin North Am 1987;10(4):541-53. PMID 3332317
30: Tremblay V, Savard J, Ivers H. Predictors of the effect of cognitive behavioral therapy for chronic insomnia comorbid with breast cancer. J Consult Clin Psych 2009;77(4):742-50. PMID 19634966
31: Van Someren EJW. Brain mechanisms of insomnia: new perspectives on causes and consequences. Physiol Rev 2021;101(3):995-1046. PMID 32790576
32: Watanabe K, Jansen PR, Savage JE, et al. Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. Nat Genet 2022;54(8):1125-32. PMID 35835914
33: Zhang Y, Su J, Wang J, et al. Cognitive behavioral therapy for insomnia combined with eszopiclone for the treatment of sleep disorder patients transferred out of the intensive care unit: A single-centred retrospective observational study. Medicine (Baltimore) 2018;97(37):e12383.** PMID 30213004
34: Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol 2018;175(16):3190-9. PMID 29318587

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Laura Palagini MD PhD

Dr. Palagini of the University Hospital of Pisa, Italy, received consultancy royalties from Bruno SPA, Fidia, Idorsia, Neuropharmed, Pfizer, and Sanofi.
See Profile

Editor

Federica Provini MD

Dr. Provini of the University of Bologna and IRCCS Institute of Neurological Sciences of Bologna received speakers' fees from Idorsia, Italfarmaco, and NeoPharmed Gentili Spa.
See Profile

Former Authors

Andrew L Chesson Jr MD
David E McCarty MD
Leisha J Cuddihy PhD
K K Jain MD†
Antonio Culebras MD FAAN FAHA FAASM

Patient Profile

Age range of presentation: 2 to 65+ years
Sex preponderance: female>male, >2:1
Heredity: familial aggregation heritability 40%
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Sleep apnoea (central, obstructive): G47.3

Nonorganic disorder of the sleep-wake schedule: F51.2

Disorders of the sleep-wake schedule: G47.2

Other specified extrapyramidal and movement disorders: G25.8

Nonorganic insomnia: F51.0

Other nonorganic sleep disorders: F51.8
ICD-11: Chronic insomnia: 7A00

Short-term insomnia: 7A01

Insomnia disorders, unspecified: 7A0Z

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Insomnia

Associated Disorders

neurodegenerative disorders, eg, Alzheimer disease
movement disorders, eg, Parkinson disease, restless legs syndrome, periodic limb movement disorder
epilepsy, eg, nocturnal seizures
painful conditions, eg, headaches
major depressive disorder
- bipolar disorder
- anxiety disorder
- stress-related disorder
- psychotic disorders
- substance use disorders
- gastroesophageal reflux disease
- urinary disturbances, eg, enuresis
- obstructive sleep apnea
- parasomnias, eg, REM sleep behavior disorder, nightmares, hypnagogic hallucinations, somnambulism, restless legs syndrome
- excessive consumption of beverages interfering with sleep, eg, alcohol, caffeine
- environmental disturbances, eg, noise, heat, cold

Differential Diagnosis

circadian rhythm disorders
restless legs syndrome

Also Relevant

Central sleep apnea due to high-altitude periodic breathing
Drug-induced parasomnias, sleep apnea, and restless legs syndrome
Idiopathic insomnia
Inadequate sleep hygiene
Jet lag disorder
- Paradoxical insomnia
- Periodic limb movements
- Pharmacological treatment of insomnia
- Psychophysiological insomnia
- Sleep and medical disorders
- Sleep disorders
- Sleep state misperception
- Sleep, trauma, and anxiety
- Stimulant-dependent sleep disorder

	• Approximately 35% of adults in U.S. and European populations have experienced insomnia within a year.
	• Rates of chronic insomnia are higher for women and the elderly.
	• Insomnia disorder may affect 7% to 10% of the adult population.

	• Early intervention including correction of poor sleep hygiene may prevent evolution into chronic insomnia.
	• Early intervention may prevent mental and medical disorders.

	• History and questionnaires are important first steps in the diagnostic evaluation of insomnia.
	• Guidelines for a diagnostic work-up have been provided by the AASM and the European Sleep Research Society.

Insomnia

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 1. Insomnia Disorder

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Table 2. Drugs Used for the Treatment of Insomnia

Special considerations

Pregnancy

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Telehealth and cognitive behavioral therapy for insomnia (CBT-I)

NonREM parasomnias

Neurologic disorders associated with obesity

Hypersomnolence

Sleep disorders in women

Sleep, stroke, and vascular dementia

Parasomnia overlap disorder and status dissociatus

Stimulant-dependent sleep disorder

This is an article preview.
Start a Free Account
to access the full version.